{"id":"W3164115667","doi":"10.1016/j.ejca.2021.03.029","title":"Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"Samsung; Genentech; Merck Sharp and Dohme; Eisai; MacroGenics; Puma Biotechnology; PharmaMar; Celgene; Jounce Therapeutics; Mylan; Genomic Health; Ipsen; Syndax Pharmaceuticals; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Olaparib; Metastatic breast cancer; Internal medicine; Oncology; Taxane; Nausea; BRCA mutation; Breast cancer; Interim analysis; Adverse effect; Cancer; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004023026,0.0003005522,0.001605732,0.0009170924,0.00002806823,0.00002585355,0.0002129093,0.00004030219,0.001396962],"category_scores_gemma":[0.000178015,0.0002597752,0.0005823449,0.002492106,0.0002063803,0.0001990503,0.00004304073,0.000829339,0.000003719687],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006927628,"about_ca_system_score_gemma":0.0009158318,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007700358,"about_ca_topic_score_gemma":0.002100003,"domain_scores_codex":[0.9931108,0.003470603,0.00214036,0.0004159194,0.0005287408,0.0003335824],"domain_scores_gemma":[0.9965128,0.0006516078,0.001333656,0.0003424072,0.0009262664,0.0002332322],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.03754733,0.004619583,0.6848266,0.0006708327,0.01048157,0.007784295,0.004237555,0.01468132,0.05979548,0.00003972512,0.0005835316,0.1747321],"study_design_scores_gemma":[0.04376302,0.0008794069,0.917326,0.005002081,0.00138629,0.0001870371,0.0003808671,0.0009904376,0.02848741,0.00008724018,0.001162411,0.0003477751],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9917503,0.003324911,0.001271998,0.001725963,0.0004532901,0.0003176907,0.0002077574,0.00001385844,0.0009342258],"genre_scores_gemma":[0.9919537,0.005772889,0.0009743486,0.0006000827,0.0003757493,0.00002140658,0.00001240358,0.00007255344,0.000216826],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2324994,"threshold_uncertainty_score":0.9999855,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04795153637465649,"score_gpt":0.4481784648935772,"score_spread":0.4002269285189207,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}